SCHOTT Pharma showed a solid year-end finish and achieved all financial targets for the fiscal year 2024. Revenues in Q4 2024 amounted to EUR 237million (+4 percent year-on-year). At constant currencies, revenue grew by 9 percent year-on-year in Q4, driving revenue growth for the fiscal year 2024 to 12 percent, the top half of the previously raised guidance. EBITDA increased even stronger to EUR 66 million (+28 percent year-on-year). This was driven by the successful expansion of capacities and more than offset the continuous ramp-up efforts and underutilization.
The EBITDA margin increased by more than five percentage points to 27.9 percent, both as reported and at constant currencies, which led to a higher margin of 26.9 percent for the fiscal year 2024 (FY 2023: 26.6 percent). At constant currencies, margin was even stronger at 27.8 percent.
Highlights
- All 2024 targets met including raised revenue guidance: 12 percent revenue growth and EBITDA margin of 27.8 percent, both at constant currencies
- Q4 2024 revenues reached EUR 237m; EBITDA margin of 27.9 percent well above prior year
- FY 2024 revenues reached EUR 957m; EBITDA margin of 26.9 percent above prior year
- Share of strong-margin high-value solutions (HVS) at 55 percent in FY 2024
- Guidance for FY 2025 reflects further strong revenue and earnings growth at constant currencies
All 2024 targets achieved
For FY 2024, SCHOTT Pharma achieved a strong revenue growth of 7 percent (at constant currencies: 12 percent). With that, revenue growth at constant currencies came in in the upper half of the increased FY 2024 guidance. This growth was primarily fuelled by the high demand for HVS products and SCHOTT Pharma’s continuous expansion of the corresponding capacities. 55 percent of revenue in FY 2024 came from strong-margin HVS, bringing the company closer to its mid-term target of above 60 percent.
SCHOTT Pharma’s profit growth in FY 2024 outperformed the already strong revenue increase. EBITDA increased by 8 percent year-on-year to EUR 258m, resulting in a margin of 26.9 percent. At constant currencies, EBITDA growth was even higher at 17 percent year-on-year. Consequently, the EBITDA margin expanded notably to a record level of 27.8 percent.
The full report is available here.